In a transaction officially set to close later this month, Syngene International Limited, a contract research, development, ...

The Baltimore Biologics Drug Substance facility will serve customers across human and animal health market segments.

Peter Bains, CEO Designate, Syngene International Ltd., said, "With one of the largest biologics R&D teams and commercial scale manufacturing capabilities in both India and the USA, we now offer a ...